EFFECTS OF PHASE I PERIODONTAL THERAPY IN CIGARETTE SMOKERS, HEATED TOBACCO PRODUCT USERS, DUAL USERS, AND NON-SMOKERS
NCT07931794, Not applicable, Not yet recruiting, Cyprus Health and Social Sciences University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | EFFECTS OF PHASE I PERIODONTAL THERAPY IN CIGARETTE SMOKERS, HEATED TOBACCO PRODUCT USERS, DUAL USERS, AND NON-SMOKERS | ClinicalTrials.gov |
| NCT number | NCT07931794 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 140 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Cyprus Health and Social Sciences University | ClinicalTrials.gov |
| Conditions | Generalized Gingivitis, Tobacco Use, Cigarette Use | ClinicalTrials.gov |
| Interventions | Phase I Periodontal Therapy | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Full-Mouth Plaque Score (FMPS) | Baseline, 1 month, and 3 months after treatment | Full-mouth plaque score (FMPS) will be assessed using the O'Leary plaque control record. The presence or absence of dental plaque will be recorded at four surfaces per tooth without a disclosing agent. FMPS will be expressed as the percentage of plaque-positive surfaces. Changes in FMPS following Phase I periodontal therapy will be compared among the four tobacco use groups. | ClinicalTrials.gov |
| Secondary | Change in Bleeding on Probing (BOP) | Baseline, 1 month, and 3 months after treatment | Bleeding on probing (BOP) will be assessed using the Ainamo and Bay Gingival Bleeding Index. Bleeding will be recorded dichotomously as present (1) or absent (0) following gentle periodontal probing. BOP will be expressed as the percentage of bleeding-positive sites. Changes in BOP following Phase I periodontal therapy will be compared among conventional cigarette smokers, heated tobacco product users, dual users, and non-smokers. | ClinicalTrials.gov |
| Other | Change in Probing Pocket Depth (PPD) | Baseline, 1 month, and 3 months after treatment | Probing pocket depth (PPD) will be measured in millimeters using a UNC-15 periodontal probe at six sites per tooth (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual). PPD is defined as the distance from the gingival margin to the base of the gingival sulcus or periodontal pocket. Changes in PPD following Phase I periodontal therapy will be evaluated at baseline, one month, and three months and compared among the four tobacco use groups. | ClinicalTrials.gov |
| Other | Change in Clinical Attachment Level (CAL) | Baseline, 1 month, and 3 months after treatment | Clinical attachment level (CAL) will be measured in millimeters using a UNC-15 periodontal probe at six sites per tooth (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual). CAL is defined as the distance from the cementoenamel junction (CEJ) to the base of the gingival sulcus or periodontal pocket. Changes in CAL following Phase I periodontal therapy will be assessed at baseline, one month, and three months and compared among the four tobacco use groups. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)